| Identification | Back Directory | [Name]
CYCLODODECANONE ISOOXIME | [CAS]
947-04-6 | [Synonyms]
LAUROLACTAM
Dodecalactam
laurinlactam
lauryllactam
Laurinolactam
Lauryl lactam
Dodecyllactam
Laurin lactam
Dodecanolactam
omega-Laurolactam
Cyclododecalactam
omega-Dodecalactam
OMEGA-LAURINLACTAM
dodecane-12-lactam
DODECANE-12-LACTAME
omega-Dodecanolactam
2-AZACYCLOTRIDECANONE
AZA-2-CYCLOTRIDECANONE
12-aminododecanolactam
Aza-cyclotridecan-2-on
Azacyclotridecan-2-one
1-Aza-2-cyclotridecanone
CYCLODODECANONE ISOOXIME
2-AZACYCLOTRIDECANONE 98%
13-azacyclotridecan-1-one
2-Oxo-dodecamethylenimine
12-amino-dodecanoicacilactam
12-AMINODODECANOIC ACID LACTAM
Dodecanoic acid, 12-amino-, lactam
12-Aminododecanoic acid lactam, Aza-2-cyclotridecanone
Aza-2-cyclotridecanone, Cyclododecanone isooxime, Laurolactam | [EINECS(EC#)]
213-424-8 | [Molecular Formula]
C12H23NO | [MDL Number]
MFCD00005104 | [MOL File]
947-04-6.mol | [Molecular Weight]
197.32 |
| Chemical Properties | Back Directory | [Melting point ]
150-153 °C(lit.)
| [Boiling point ]
334.44°C (rough estimate) | [density ]
0.9415 (rough estimate) | [vapor pressure ]
0.001Pa at 20℃ | [refractive index ]
1.4400 (estimate) | [Fp ]
195 °C | [form ]
powder to crystal | [pka]
16.91±0.20(Predicted) | [color ]
White to Almost white | [Water Solubility ]
223mg/L at 20℃ | [BRN ]
122031 | [LogP]
2.71 at 20℃ | [EPA Substance Registry System]
Azacyclotridecan-2-one (947-04-6) |
| Hazard Information | Back Directory | [Chemical Properties]
Dry PowderSolid; very faintly beige crystalline lumps. Virtually insol in water. | [Definition]
ChEBI: Laurolactam is an azamacrocycle and a keratan 6'-sulfate. | [Preparation]
One route to dodecyllactam is from butadiene as follows:
Butadiene is trimerized with a Ziegler-Natta catalyst to give 1,5,9-cyclododecatriene
which is then hydrogenated to cyclododecane. Dodecyllactam
is then obtained by a series of reactions similar to those used to prepare
caprolactam from cyclohexane. | [Health Hazard]
The acute oral LD50 was 2,330 mg/kg bw (rat) with central nervous system stimulation (trembling, convulsive twitches, ataxia) as the main clinical sign appearing at about 1,580 mg/kg bw. The dermal LD50 was greater than 2,000 mg/kg bw (rat). Decreased food consumption and stagnation of body weight development were noted. Validacute inhalation studies are not available. Azacyclotridecan-2-one was not irritating to the rabbit skin or eye (OECD TG 404, 405). It was not sensitizing in aguinea pig maximization test (OECD TG 406; 1981). | [Purification Methods]
2-Azacyclotridecanone crystallises from CHCl3 and is stored over P2O5 in a vacuum desiccator. [Beilstein 26/1 V 566.] |
|
|